On October 9, California Governor Jerry Brown signed SB 17, legislation mandating advance notice and price transparency reporting for drugs experiencing greater than 16% increases in WAC over three calendar years and new drugs introduced at a WAC above the Medicare Part D specialty drug threshold.  The legislation will take effect January 1, 2018, although the reporting requirements to the Office of Statewide Health Planning and Development will begin in the first quarter of 2019.

California now joins Maryland, New York, and Nevada in having enacted pharmaceutical cost control and/or transparency legislation in 2017.  Additional information on SB 17 can be found here and here.

Copyright © 2019, Foley Hoag LLP. All rights reserved.